U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Contributed by: Business Wire

Logo

Tags

Oncology

Health

FDA

General Health

Clinical Trials

Pharmaceutical

Biotechnology

Sonrotoclax

More Like This

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024